Question · asked by 1 review

Infliximab 5–10 mg/kg vs placebo: Withdrawals due to adverse events

Population: Patients with active Crohn's disease
Intervention: Infliximab 5–10 mg/kg
Comparison: placebo
Outcome: Withdrawals due to adverse events

The review found no eligible studies for this question.

What each review found

No studies found 1 · 50%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Finding	Effect	Studies	GRADE certainty
Infliximab 5–10 mg/kg vs placebo Withdrawals due to adverse events · active Crohn's disease The review found no eligible studies for this question. Infliximab for medical induction of remission in Crohn's disease (2023) · Cochrane Headline outcomes only	no estimate extracted	Not reported	No studies found
Infliximab 5–10 mg/kg vs placebo Withdrawals due to adverse events · active Crohn's disease It is very uncertain whether infliximab 5–10 mg/kg changes withdrawals due to adverse events compared with placebo (very low certainty). Infliximab for medical induction of remission in Crohn's disease (2023) · Cochrane Headline outcomes only	RR 2.5 [0.12, 50.54]	1 study · 94 participants	Very low

Findings are shown side by side, never pooled across reviews.

The reviews

Review	Searched up to	Included studies	AMSTAR 2
Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only	Not reported	Not extracted	Not assessed

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.